Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.
Clinic of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Bellinzona and Lugano, Switzerland; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):422-430. doi: 10.1016/j.clml.2020.01.018. Epub 2020 Feb 4.
The aim of this systematic review was to examine published data about the potential role of Fluorine-18-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography (F-FDG PET or PET/CT) in patients affected by mantle cell lymphoma (MCL). A comprehensive computer literature search of Scopus, PubMed/MEDLINE, and Embase databases was conducted, including articles indexed up to November, 2019; 25 studies or subsets in studies analyzing the value of F-FDG PET or PET/CT in patients with MCL were eligible for inclusion. From the analyses of the selected studies, the following main findings are described: (1) MCL are F-FDG-avid in most of cases, especially nodal lesions, but bone marrow and gastrointestinal disease localizations have low F-FDG avidity; (2) F-FDG PET/CT seems to be helpful in staging setting, showing a better diagnostic performance than conventional imaging and a positive impact on clinical stage; (3) F-FDG PET/CT is useful in evaluating treatment response, especially after chemotherapy and transplantation; and (4) metabolic response after therapy seems to have a prognostic role. Despite several limitations affecting this analysis, especially related to the heterogeneity of the studies included, MCL is an F-FDG-avid lymphoma in most of the cases, with the exception of bone marrow and gastrointestinal disease. Moreover, F-FDG PET/CT seems to be useful in evaluating treatment response and prognosis.
本系统评价的目的是研究已发表的数据，探讨氟-18-氟代脱氧葡萄糖正电子发射断层扫描或正电子发射断层扫描/计算机断层扫描（F-FDG PET 或 PET/CT）在套细胞淋巴瘤（MCL）患者中的潜在作用。我们对 Scopus、PubMed/MEDLINE 和 Embase 数据库进行了全面的计算机文献检索，包括截至 2019 年 11 月索引的文章；25 项研究或分析 F-FDG PET 或 PET/CT 在 MCL 患者中价值的研究亚组符合纳入标准。从对选定研究的分析中，描述了以下主要发现：（1）MCL 在大多数情况下摄取 F-FDG，尤其是淋巴结病变，但骨髓和胃肠道疾病部位摄取 F-FDG 的能力较低；（2）F-FDG PET/CT 似乎有助于分期，其诊断性能优于常规影像学检查，并对临床分期有积极影响；（3）F-FDG PET/CT 可用于评估治疗反应，尤其是在化疗和移植后；（4）治疗后的代谢反应似乎具有预后作用。尽管这项分析存在一些局限性，尤其是与纳入研究的异质性有关，但除了骨髓和胃肠道疾病外，MCL 在大多数情况下是一种摄取 F-FDG 的淋巴瘤。此外，F-FDG PET/CT 似乎在评估治疗反应和预后方面有用。
